AOP Health US LLC: RAPIBLYK(R) (landiolol) Approved by FDA for Use in Pediatric Patients with Supraventricular Tachycardia

RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...
MPR

Rapiblyk Receives FDA Approval for Pediatric SVT Treatment

Approval was supported by the phase 3 LANDI-PED study, which demonstrated significant heart rate reduction and conversion to normal sinus rhythm in pediatric patients.

Corify Care Receives FDA Clearance for ACORYS® -- Introducing Instant, 4-D Electroanatomical Cardiac Mapping in Real-time

Corify Care today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the ACORYS® System, ...

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in ...

TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first new FDA-approved treatment for fibromyalgia ...